New drug combo targets Hard-to-Treat cancers with gene mutations

NCT ID NCT03218826

First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 22 times

Summary

This early-phase study tests a new drug (AZD8186) combined with chemotherapy (docetaxel) in people with advanced solid tumors that have certain gene changes (PTEN or PIK3CB mutations). The main goals are to find the safest dose and understand side effects. About 23 adults whose cancer has spread or cannot be removed by surgery, and who have no other good treatment options, are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IIIA PROSTATE CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland, 20892, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

  • UCHealth University of Colorado Hospital

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.